A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Trial Profile

A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Siltuximab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 19 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jun 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2010-0623).
    • 29 May 2012 Planned end date changed from 1 Apr 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top